4521.T Stock: Kaken Pharmaceutical Co., Ltd. Stock Price, Analysis & Insights
Get live 4521.T stock price $3860.00, comprehensive Kaken Pharmaceutical Co., Ltd. stock analysis, charts, news, and expert forecast. Real-time 4521.T stock data and investment insights.
Loading chart data...
Kaken Pharmaceutical Co., Ltd. (4521.T) Overview
Kaken Pharmaceutical Co., Ltd. (4521.T) is a publicly traded company in the Healthcare sector , specifically within the Drug Manufacturers - Specialty & Generic industry . As of the latest trading session, 4521.T trades at $3860.00 with a market capitalization of 146.17B . Over the past 52 weeks, 4521.T has traded between $3540.00 and $4445.00 , with the current price positioned at approximatel...
Key Takeaways
- Operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic)
- Market cap: 146.17B
- Current price: $3860.00
- 52-week range: $3540.00 - $4445.00
- P/E ratio: 265.84
Investment Score
A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Kaken Pharmaceutical Co., Ltd. is involved in the development, manufacturing, and commercialization of a diverse range of medical goods, health devices, and agricultural chemicals, serving both domestic and global markets. Their extensive product por...
Company Information
- CEO
- Hiroyuki Horiuchi
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 1135
Contact Information
- Website
- https://www.kaken.co.jp
- Address
- 28-8, Honkomagome 2-chome
- Country
- JP
Investment Analysis & Business Insights
Investment Highlights
✓ Market leader with 146.2 billion market capitalization
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 265.8)
✓ Lower volatility stock (Beta: 0.12) may provide portfolio stability
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Kaken Pharmaceutical Co., Ltd. shareholders
- ⚠Market volatility can significantly impact stock price, especially for mid-cap stocks
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Kaken Pharmaceutical Co., Ltd.
- ⚠Investors should consider how Kaken Pharmaceutical Co., Ltd. fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 265.8) requires strong growth to justify
Market Cap
146.17B
P/E Ratio (TTM)
265.84
Beta
0.12
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare 4521.T with peer companies:
- Price
- $2,520.00-6.15% (1D)
- Market cap
- 140.50B
- Price
- $2,079.00-1.40% (1D)
- Market cap
- 101.25B
- Price
- $3,200.00+0.16% (1D)
- Market cap
- 113.44B
- Price
- $3,905.00+0.77% (1D)
- Market cap
- 161.87B
- Price
- $3,755.00-0.66% (1D)
- Market cap
- 184.85B
- Price
- $2,143.00-0.23% (1D)
- Market cap
- 94.46B
- Price
- $1,150.00+0.97% (1D)
- Market cap
- 66.06B
- Price
- $3,640.00-0.68% (1D)
- Market cap
- 136.44B
- Price
- $1,070.00-0.09% (1D)
- Market cap
- 135.37B
- Price
- $1,685.00+0.30% (1D)
- Market cap
- 165.98B
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
43/100 ⭐⭐⭐
- Overall
- -1.0%
- NYSE
- -1.6%
- NASDAQ
- -0.4%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Financial Services | +0.3% | +1.3% | +1.9% | 19.8 | 83/100⭐⭐⭐⭐⭐ |
| Technology | +0.8% | +1.1% | +3.0% | 52.0 | 76/100⭐⭐⭐⭐⭐ |
| Basic Materials | +0.8% | +0.3% | +1.9% | 27.9 | 69/100⭐⭐⭐⭐ |
| Industrials | -0.3% | -0.9% | +2.7% | 43.0 | 64/100⭐⭐⭐⭐ |
| Communication Services | -0.8% | -1.3% | +0.4% | 21.9 | 48/100⭐⭐⭐ |
| Consumer Defensive | +0.6% | +1.6% | -2.5% | 31.2 | 44/100⭐⭐⭐ |
| Healthcare | -1.0% | -2.0% | +1.5% | 30.5 | 43/100⭐⭐⭐ |
| Real Estate | +0.5% | -1.1% | -0.0% | 50.0 | 33/100⭐⭐ |
| Energy | +0.5% | -3.6% | -0.0% | 35.9 | 31/100⭐⭐ |
| Utilities | +2.0% | -1.3% | -5.1% | 26.1 | 31/100⭐⭐ |
| Consumer Cyclical | -0.3% | +0.3% | -0.2% | 55.8 | 28/100⭐⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-06-13.